---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-115119"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:36:23.170044+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Larimar reports Q4 net loss $62.5M; BLA for nomlabofusp on track for June 2026 submission

## Summary
- Net loss Q4 2025 $62.5M ($0.73/sh) vs $28.8M ($0.45/sh) in Q4 2024; R&D expenses rose to $59.4M.
- Full-year 2025 net loss $165.7M ($2.27/sh) vs $80.6M ($1.32/sh) in 2024.
- Cash & equivalents $136.9M at Dec 31, 2025; pro forma $244.5M after Feb 2026 $107.6M offering, runway into Q2 2027.
- FDA granted Breakthrough Therapy Designation for nomlabofusp in FA; FDA alignment on FXN as surrogate endpoint.
- Phase 3 confirmatory study screening to start Q2 2026; topline open-label data expected Q2 2026; BLA submission June 2026.

## SEC filing metadata
- accession: 0001193125-26-115119
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000119312526115119/0001193125-26-115119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000119312526115119/lrmr-20260319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-115119
- JSON: https://secwatch.observer/filing/0001193125-26-115119.json
- Plain text: https://secwatch.observer/filing/0001193125-26-115119.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.